4,109 Shares in Pro-Dex, Inc. $PDEX Acquired by Morgan Dempsey Capital Management LLC

Morgan Dempsey Capital Management LLC purchased a new position in shares of Pro-Dex, Inc. (NASDAQ:PDEXFree Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 4,109 shares of the medical instruments supplier’s stock, valued at approximately $179,000.

Other large investors have also recently made changes to their positions in the company. Cubist Systematic Strategies LLC purchased a new stake in shares of Pro-Dex during the first quarter worth approximately $170,000. Bank of New York Mellon Corp grew its holdings in Pro-Dex by 48.5% in the 1st quarter. Bank of New York Mellon Corp now owns 6,415 shares of the medical instruments supplier’s stock valued at $318,000 after buying an additional 2,096 shares in the last quarter. Jane Street Group LLC purchased a new stake in Pro-Dex in the 1st quarter valued at $321,000. American Century Companies Inc. grew its holdings in Pro-Dex by 3.0% in the 1st quarter. American Century Companies Inc. now owns 12,301 shares of the medical instruments supplier’s stock valued at $610,000 after buying an additional 355 shares in the last quarter. Finally, Ritholtz Wealth Management grew its holdings in Pro-Dex by 32.4% in the 2nd quarter. Ritholtz Wealth Management now owns 21,102 shares of the medical instruments supplier’s stock valued at $921,000 after buying an additional 5,158 shares in the last quarter. 15.28% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on PDEX. Wall Street Zen cut Pro-Dex from a “buy” rating to a “hold” rating in a report on Saturday, August 16th. Weiss Ratings restated a “hold (c+)” rating on shares of Pro-Dex in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

Check Out Our Latest Stock Analysis on PDEX

Pro-Dex Stock Performance

NASDAQ PDEX opened at $26.22 on Friday. The stock has a market cap of $86.00 million, a PE ratio of 9.71 and a beta of -0.11. The company has a current ratio of 3.23, a quick ratio of 1.71 and a debt-to-equity ratio of 0.25. Pro-Dex, Inc. has a twelve month low of $23.47 and a twelve month high of $70.26. The stock has a fifty day simple moving average of $37.32 and a 200-day simple moving average of $44.68.

Pro-Dex (NASDAQ:PDEXGet Free Report) last released its quarterly earnings results on Thursday, September 4th. The medical instruments supplier reported $0.36 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.11). The business had revenue of $17.49 million for the quarter, compared to analysts’ expectations of $17.90 million. Pro-Dex had a return on equity of 26.67% and a net margin of 13.48%. Equities analysts anticipate that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Pro-Dex Profile

(Free Report)

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

Recommended Stories

Want to see what other hedge funds are holding PDEX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pro-Dex, Inc. (NASDAQ:PDEXFree Report).

Institutional Ownership by Quarter for Pro-Dex (NASDAQ:PDEX)

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.